- Prescribing Advice for GPs - http://www.prescriber.org.uk -
NICE Guidance - February 2012
Posted By Matthew Robinson On February 22, 2012 @ 10:11 am In Prescribing Extra - Other | 3 Comments
The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of February 2012. This month there is one technology appraisal that impact upon primary care.
Exenatide prolonged release (Bydureon®) has been reviewed in a technology appraisal and is approved for use in combination with oral therapies when glycaemic control is inadequate (HbA1c > 7.5% or 59mmol/mol) and:
It is also advised the treatment is reviewed at 6 months and discontinued if:
Action: Clinicians should be aware of this new guidance and implement any necessary changes to practice.
Article printed from Prescribing Advice for GPs: http://www.prescriber.org.uk
URL to article: http://www.prescriber.org.uk/2012/02/nice-guidance-february-2012/